Close Menu

To Buy or Not to Buy

At Forbes's Science Business blog Matthew Herper wonders whether Amgen should acquire Human Genome Sciences. Biotech analyst Geoffrey Porges says it should, and that the price tag could be as high as $6.5 billion. Porges points out that Benlysta, Human Genome's lupus drug, is "one of the hotter biotech products" and that Amgen has more to offer Human Genome than GlaxoSmithKline, which has the rights to co-market Benlysta, does.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.